Literature DB >> 2964515

Growth inhibitory effect of recombinant alpha and beta interferon on human glioma cells.

W K Yung1, P A Steck, P J Kelleher, R P Moser, M G Rosenblum.   

Abstract

Growth inhibitory activity of recombinant alpha and beta interferon on two human glioma cell lines, EFC-2 and KE cells, was determined by two different growth assays. Recombinant beta interferon showed a slight growth inhibitory effect on EFC-2 cells at day 3, and maximum inhibition was seen on day 6 with an ID50 of 50 U/ml. Recombinant alpha interferon showed no significant growth inhibition at any concentration. KE cells were resistant to both recombinant alpha and beta interferon. The growth inhibitory activity of recombinant beta interferon on EFC-2 cells was not blocked by recombinant alpha interferon, although recombinant alpha and beta interferons shared same receptors on EFC-2 cells. Addition of DFMO (alpha-difluoromethylornithine) to interferon in the media showed additive effect rather than synergistic effect in growth inhibition of glioma cells. Out of 7 glioma cell lines tested, 4 showed heterogeneous sensitivity to recombinant beta interferon, and all were resistant to recombinant alpha interferon. These results suggest a differential sensitivity of EFC-2 cells to recombinant beta interferon, as well as a heterogeneous sensitivity to recombinant beta interferon among different glioma cell lines.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2964515     DOI: 10.1007/bf00148389

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  15 in total

1.  Surface-specific iodination of membrane proteins of viruses and eucaryotic cells using 1,3,4,6-tetrachloro-3alpha,6alpha-diphenylglycoluril.

Authors:  M A Markwell; C F Fox
Journal:  Biochemistry       Date:  1978-10-31       Impact factor: 3.162

2.  Growth-inhibitory activity of human recombinant beta-interferon (GKT-beta) in vitro.

Authors:  Y Shimada; M Shimoyama
Journal:  Gan       Date:  1984-12

3.  Isolation, karyotype, and clonal growth of heterogeneous subpopulations of human malignant gliomas.

Authors:  J R Shapiro; W K Yung; W R Shapiro
Journal:  Cancer Res       Date:  1981-06       Impact factor: 12.701

4.  Survival in glioblastoma: historical perspective.

Authors:  M Salcman
Journal:  Neurosurgery       Date:  1980-11       Impact factor: 4.654

5.  High-affinity binding of 125I-labeled mouse interferon to a specific cell surface receptor. IV. Mouse gamma interferon and cholera toxin do not compete for the common receptor site of alpha / beta interferon.

Authors:  M Aguet; F Belardelli; B Blanchard; F Marcucci; I Gresser
Journal:  Virology       Date:  1982-03       Impact factor: 3.616

6.  Local administration of interferon for malignant brain tumors.

Authors:  Y Nakagawa; K Hirakawa; S Ueda; K Suzuki; S Fukuma; T Kishida; J Imanishi; T Amagai
Journal:  Cancer Treat Rep       Date:  1983-09

7.  Differential effects of inhibition of polyamine biosynthesis on cell cycle traverse and structure of the prematurely condensed chromosomes of normal and transformed cells.

Authors:  P S Sunkara; M B Pargac; K Nishioka; P N Rao
Journal:  J Cell Physiol       Date:  1979-03       Impact factor: 6.384

8.  Effect of human leukocyte interferon on malignant brain tumors.

Authors:  K Hirakawa; S Ueda; Y Nakagawa; K Suzuki; S Fukuma; M Kita; J Imanishi; T Kishida
Journal:  Cancer       Date:  1983-06-01       Impact factor: 6.860

9.  Human brain tumor--derived cell lines: growth rate reduced by human fibroblast interferon.

Authors:  A W Cook; W A Carter; F Nidzgorski; L Akhtar
Journal:  Science       Date:  1983-02-18       Impact factor: 47.728

10.  Central nervous system toxicity of interferon.

Authors:  A Z Rohatiner; P F Prior; A C Burton; A T Smith; F R Balkwill; T A Lister
Journal:  Br J Cancer       Date:  1983-03       Impact factor: 7.640

View more
  7 in total

1.  Phase I trial of pegylated interferon-alpha-2b in young patients with plexiform neurofibromas.

Authors:  R I Jakacki; E Dombi; D M Potter; S Goldman; J C Allen; I F Pollack; B C Widemann
Journal:  Neurology       Date:  2011-01-18       Impact factor: 9.910

2.  A pilot study of recombinant interferon beta (IFN-beta ser) in patients with recurrent glioma.

Authors:  W K Yung; A M Castellanos; P Van Tassel; R P Moser; S G Marcus
Journal:  J Neurooncol       Date:  1990-08       Impact factor: 4.130

3.  High dose oral tamoxifen and subcutaneous interferon alpha-2a for recurrent glioma.

Authors:  S M Chang; F G Barker; S L Huhn; M K Nicholas; M Page; J Rabbitt; M D Prados
Journal:  J Neurooncol       Date:  1998-04       Impact factor: 4.130

4.  The effects of local and systemic interferon beta (Fiblaferon) on supratentorial malignant cerebral glioma--a phase II study.

Authors:  K R von Wild; T H Knocke
Journal:  Neurosurg Rev       Date:  1991       Impact factor: 3.042

5.  Phase II study of peginterferon alpha-2b for patients with unresectable or recurrent craniopharyngiomas: a Pediatric Brain Tumor Consortium report.

Authors:  Stewart Goldman; Ian F Pollack; Regina I Jakacki; Catherine A Billups; Tina Y Poussaint; Adekunle M Adesina; Ashok Panigrahy; Donald W Parsons; Alberto Broniscer; Giles W Robinson; Nathan J Robison; Sonia Partap; Lindsay B Kilburn; Arzu Onar-Thomas; Ira J Dunkel; Maryam Fouladi
Journal:  Neuro Oncol       Date:  2020-11-26       Impact factor: 12.300

Review 6.  In vitro chemosensitivity testing and its clinical application in human gliomas.

Authors:  W K Yung
Journal:  Neurosurg Rev       Date:  1989       Impact factor: 3.042

7.  Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.

Authors:  Timothy F Cloughesy; Aaron Y Mochizuki; Joey R Orpilla; Willy Hugo; Alexander H Lee; Tom B Davidson; Anthony C Wang; Benjamin M Ellingson; Julie A Rytlewski; Catherine M Sanders; Eric S Kawaguchi; Lin Du; Gang Li; William H Yong; Sarah C Gaffey; Adam L Cohen; Ingo K Mellinghoff; Eudocia Q Lee; David A Reardon; Barbara J O'Brien; Nicholas A Butowski; Phioanh L Nghiemphu; Jennifer L Clarke; Isabel C Arrillaga-Romany; Howard Colman; Thomas J Kaley; John F de Groot; Linda M Liau; Patrick Y Wen; Robert M Prins
Journal:  Nat Med       Date:  2019-02-11       Impact factor: 53.440

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.